CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre
Details
Publication Year 2023-05,Volume 64,Issue #2,Page 194-203
Journal Title
Australasian Journal of Dermatology
Publication Type
Review
Abstract
The CD30-postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T-cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia.
Publisher
Wiley
Keywords
Humans; Australia; Ki-1 Antigen/metabolism; *Lymphomatoid Papulosis/diagnosis/therapy/pathology; *Lymphoproliferative Disorders/diagnosis/therapy; *Skin Neoplasms/diagnosis/therapy/pathology; CD30 lymphoproliferative disorders; cutaneous T cell lymphoma; lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma
Department(s)
Surgical Oncology; Radiation Oncology; Pathology; Clinical Haematology
PubMed ID
36892928
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-08-08 01:28:49
Last Modified: 2023-08-08 01:31:07

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙